

**PCSK1N / PROSAAS Antibody (aa182-193)**  
**Goat Polyclonal Antibody**  
**Catalog # ALS16157**

**Specification**

---

**PCSK1N / PROSAAS Antibody (aa182-193) - Product Information**

Application	IHC
Primary Accession	<a href="#">Q9UHG2</a>
Reactivity	Human, Monkey
Host	Goat
Clonality	Polyclonal
Calculated MW	27kDa KDa

**PCSK1N / PROSAAS Antibody (aa182-193) - Additional Information**

**Gene ID** 27344

**Other Names**

ProSAAS, Proprotein convertase subtilisin/kexin type 1 inhibitor, Proprotein convertase 1 inhibitor, pro-SAAS, KEP, Big SAAS, b-SAAS, Little SAAS, I-SAAS, N-proSAAS, Big PEN-LEN, b-PEN-LEN, SAAS CT(1-49), PEN, Little LEN, I-LEN, Big LEN, b-LEN, SAAS CT(25-40), PCSK1N

**Target/Specificity**

Human PCSK1N / PROSAAS.

**Reconstitution & Storage**

Store at -20°C. Minimize freezing and thawing.

**Precautions**

PCSK1N / PROSAAS Antibody (aa182-193) is for research use only and not for use in diagnostic or therapeutic procedures.

**PCSK1N / PROSAAS Antibody (aa182-193) - Protein Information**

**Name** PCSK1N

**Function**

May function in the control of the neuroendocrine secretory pathway. Proposed be a specific endogenous inhibitor of PCSK1. ProSAAS and Big PEN-LEN, both containing the C-terminal inhibitory domain, but not the further processed peptides reduce PCSK1 activity in the endoplasmic reticulum and Golgi. It reduces the activity of the 84 kDa form but not the autocatalytically derived 66 kDa form of PCSK1. Subsequent processing of proSAAS may eliminate the inhibition. Slows down convertase-mediated processing of proproiomelanocortin and proenkephalin. May control the intracellular timing of PCSK1 rather than its total level of activity (By similarity).

**Cellular Location**

Secreted {ECO:0000250|UniProtKB:Q9QXV0}. Golgi apparatus, trans-Golgi network

{ECO:0000250|UniProtKB:Q9QXV0}. Note=A N-terminal processed peptide, probably Big SAAS or Little SAAS, is accumulated in cytoplasmic protein tau deposits in frontotemporal dementia and parkinsonism linked to chromosome 17 (Pick disease), Alzheimer disease and amyotrophic lateral sclerosis- parkinsonism/dementia complex 1 (Guam disease)

#### **Tissue Location**


Expressed in brain and pancreas.

#### **PCSK1N / PROSAAS Antibody (aa182-193) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

#### **PCSK1N / PROSAAS Antibody (aa182-193) - Images**



Anti-PCSK1N / PROSAAS antibody IHC staining of human pancreas.

#### **PCSK1N / PROSAAS Antibody (aa182-193) - Background**

May function in the control of the neuroendocrine secretory pathway. Proposed to be a specific endogenous inhibitor of PCSK1. ProSAAS and Big PEN-LEN, both containing the C-terminal inhibitory domain, but not the further processed peptides reduce PCSK1 activity in the endoplasmic reticulum and Golgi. It reduces the activity of the 84 kDa form but not the autocatalytically derived 66 kDa form of PCSK1. Subsequent processing of proSAAS may eliminate the inhibition. Slows down convertase-mediated processing of proopiomelanocortin and proenkephalin. May control the intracellular timing of PCSK1 rather than its total level of activity. The function of the processed secreted peptides is not known (By similarity).

#### **PCSK1N / PROSAAS Antibody (aa182-193) - References**

- Fricker L., et al. J. Neurosci. 20:639-648(2000).  
Basak A., et al. J. Biol. Chem. 276:32720-32728(2001).  
Kikuchi K., et al. Biochem. Biophys. Res. Commun. 308:646-654(2003).

Wada M., et al. *Neurosci. Lett.* 356:49-52(2004).  
Nilsson J., et al. *Nat. Methods* 6:809-811(2009).